Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Chubb
Chinese Patent Office
Baxter
Covington
Medtronic

Generated: August 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,107,921

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,107,921 protect, and when does it expire?

Patent 9,107,921 protects TUXARIN ER and is included in one NDA.

Summary for Patent: 9,107,921
Title:Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Abstract: A pharmaceutical tablet for oral administration once every 12 hours is provided. The tablet includes a first active agent that is a tri-oxy active agent, a second active agent, and a release rate controlling non-ionic oxyl-containing hydrophilic polymer. The tablet is a matrix tablet and a single-dose administration of one or more tablets to a subject under fasted conditions provides a mean Cm.about. for each of the first active agent and the second active agent that is 70% to 135% of a respective mean Cm.about. provided by administering an immediate release oral dosage form to a subject under fasted conditions every 4 to 6 hours over a 12 hour time period, wherein cumulative dosage amounts administered over the 12 hour time period of each active agent is equivalent to the respective amount of each active agent in the pharmaceutical tablet.
Inventor(s): Giliyar; Chandrashekar (North Maple Grove, MN), Nachaegari; Satish Kumar (Salt Lake City, UT), Machiappan; Chidambaram (Salt Lake City, UT), Patel; Mahesh V. (Salt Lake City, UT), Venkateshwaran; Srinivasan (Salt Lake City, UT)
Assignee: Spriaso LLC (Salt Lake City, UT)
Application Number:14/555,043
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 9,107,921

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mainpointe TUXARIN ER chlorpheniramine maleate; codeine phosphate TABLET, EXTENDED RELEASE;ORAL 206323-001 Jun 22, 2015 RX No No   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Express Scripts
Farmers Insurance
Boehringer Ingelheim
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.